HBAR news live: Holds above MA-20 support — mixed oscillators signal potential for sideways action

Traders Union
All News
Crypto
Hedera Drops 1.59% to $0.238 Today

Highlights

Hedera (HBAR) trades at $0.238, above the MA-20 ($0.2328) and well above MA-200 ($0.2008), but faces immediate resistance at MA-50 ($0.2402).
The newly formed Hedera Enterprise Adoption Team (HEAT), led by Rob Allen, is accelerating enterprise blockchain adoption, driving growth in decentralized identity, supply chain, and stablecoin sectors.
Momentum indicators are mixed, but three out of four weekly signals (RSI, ADX, MACD) suggest over 80% probability of a price increase, with projected weekly fluctuation between $0.2253 and $0.2286.

Enterprise adoption drives network growth amid institutional interest

Hedera has formed the Hedera Enterprise Adoption Team (HEAT) led by Rob Allen to accelerate projects for Council Members from proof of concept to enterprise-grade blockchain solutions, bolstering its role in large-scale distributed ledger use cases. The network reports ongoing growth in adoption, especially in areas like decentralized identity, supply chain tracking, and stablecoin deployment, supported by its global council governance and strong transaction throughput. Continued interest from institutional investors and expanding DeFi integrations also underpin HBAR’s position in the market.

Mixed momentum as overbought signals clash with soft price action

Momentum analysis shows that the daily MACD gives a buy signal, but the ADX is low at 10.61, suggesting a weak underlying trend. RSI and CCI on D1 are bullish but approach overbought territory, while the Stoch RSI is already overbought, indicating some risk of a pullback. BBP is neutral, showing no clear dominance among buyers or sellers intraday. The Awesome Oscillator, pointing down, matches the daily movement: a $0.00385 drop or 1.59% decline. There was effectively no gap at the open, with the current price near today’s low of $0.2374. Intraday volatility is moderate, and the tone shows pressure after the open. Oscillators are mixed, revealing a divergence between upward momentum on some indicators and overbought warnings, which contrasts the intraday softness observed in price.

Upside favored as buy signals outweigh limited downside risk

For the next week, HBAR is expected to fluctuate between $0.2253 and $0.2286, with an average price projection of $0.2269. Out of four major weekly indicators (RSI, ADX, MACD, MA-50), three point to a buy setup, resulting in a very high probability (more than 80%) of a price increase. The likelihood of a decline is correspondingly very low. The baseline scenario envisions continued sideways movement near current levels. In a bullish scenario, the price could break above the $0.2402 resistance, opening room for further gains. Conversely, a bearish move below the $0.2327 support may trigger further weakness toward the lower end of the projected range.

Anton Kharitonov, expert at Traders Union, sees Hedera (HBAR) trading in a technically indecisive zone, with upward momentum constrained by immediate resistance at $0.2402 and lingering risk of a pullback as overbought signals emerge. While ongoing enterprise developments and institutional interest strengthen the long-term outlook, short-term signals—especially the low ADX and mixed oscillators—warrant a cautious stance. Kharitonov believes the price is likely to move sideways within the projected range unless key support or resistance levels are broken decisively. "Base case remains neutral until HBAR breaks above $0.2402 or falls below $0.2327—until then, caution is warranted."

Last time we reported that price is expected to consolidate within a sideways or lower bias as breakout risks remain subdued. Previously it was noted that institutional interest in HBAR is increasing following recent ETF filings and growing enterprise adoption.

Source of Data: HBAR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.